53933-60-1

Basic information

• Product Name: SULINDAC RELATED COMPOUND A (20 MG) (TRANS-SULINDAC)
• Synonyms: trans-Sulindac;Sulindac Related Compound A (20 mg) ((E)-2-{5-Fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid);SULINDAC RELATED COMPOUND A (20 MG) (TRANS-SULINDAC);(E)-(±)-5-fluoro-2-methyl-1-[[4-(methylsulphinyl)phenyl]methylene]-1H-indene-3-acetic acid;5-Fluoro-2-methyl-1-[(E)-[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid;(E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid;Einecs 258-873-0;Sulindac Related CoMpound A
• CAS NO: 53933-60-1
• Molecular Formula: C₂₀H₁₇FO₃S
• Molecular Weight: 356.4105832
• EINECS: 258-873-0
• Mol File: 53933-60-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 581.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.38±0.1 g/cm3(Predicted)
• PKA: 4.26±0.10(Predicted)
• CAS DataBase Reference: SULINDAC RELATED COMPOUND A (20 MG) (TRANS-SULINDAC)(CAS DataBase Reference)
• NIST Chemistry Reference: SULINDAC RELATED COMPOUND A (20 MG) (TRANS-SULINDAC)(53933-60-1)
• EPA Substance Registry System: SULINDAC RELATED COMPOUND A (20 MG) (TRANS-SULINDAC)(53933-60-1)

Safety Data

• Hazardous Substances Data: 53933-60-1(Hazardous Substances Data)

Usage

Description

SULINDAC RELATED COMPOUND A (20 MG) (TRANS-SULINDAC) is a pharmaceutical compound that is an isomer of (Z)-Sulindac (S699215), which is a non-steroidal anti-inflammatory drug (NSAID). It possesses anti-inflammatory properties and is used for various medical applications.

Uses

Used in Pharmaceutical Industry:
SULINDAC RELATED COMPOUND A (20 MG) (TRANS-SULINDAC) is used as an active pharmaceutical ingredient for the treatment of inflammation and pain relief. It is particularly effective in managing conditions such as arthritis, where it helps to reduce swelling, pain, and stiffness.
Additionally, due to its anti-inflammatory properties, TRANS-SULINDAC may also be used as a potential therapeutic agent for other inflammatory conditions, although further research is needed to confirm its efficacy and safety in these applications.

InChI:InChI=1/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)

Upstream product

• 49627-27-2 5-fluoro-2-methyl-1-(4-methylsulfanylbenzylidene)-3-indenylacetic acid 
• 61812-45-1 sulindac sulfide 

Downstream Products

• 144498-50-0 {6-Fluoro-3-[1-(4-methanesulfinyl-phenyl)-meth-(E)-ylidene]-2-methyl-3H-inden-1-yl}-methanol 
• 144498-51-1 6-Fluoro-3-[1-(4-methanesulfinyl-phenyl)-meth-(E)-ylidene]-2-methyl-3H-indene-1-carbaldehyde 
• 144498-49-7 6-Fluoro-3-[1-(4-methanesulfonyl-phenyl)-meth-(E)-ylidene]-2-methyl-3H-indene-1-carbaldehyde 
• 144498-48-6 {6-Fluoro-3-[1-(4-methanesulfonyl-phenyl)-meth-(E)-ylidene]-2-methyl-3H-inden-1-yl}-methanol 
• 41201-75-6 6-Fluoro-3-[1-(4-methanesulfinyl-phenyl)-meth-(E)-ylidene]-2-methyl-3H-indene-1-carboxylic acid 

Relevant articles and documents

Catalyst-free visible light-mediated selective oxidation of sulfides into sulfoxides under clean conditions

A facile and efficient visible-light-mediated method for directly converting sulfides into sulfoxides under clean conditions without using any photocatalysts is reported. This method exhibited favourable compatibility with functional groups and afforded a series of sulfoxides with high selectivity and yields. Moreover, in order to shed more light on such a transformation, detailed mechanism studies were carried out both experimentally and theoretically. The readily accessible, low-cost and eco-friendly nature of the developed method will endow it with attractive applications in chemical synthesis.

Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group

A process for the oxidation of thioethers to sulfoxides or sulfones or for the oxidation of sulfoxides to sulfones by treatment of thioethers or sulfoxides with an oxidizing amount of ε-phthalimidoperhexanoic acid is particularly useful for the preparation of compounds of industrial interest, in particular pharmaceuticals for human or veterinary use.

Lactone compounds for treating patients with precancerous lesions

Substituted lactone compounds are useful in the treatment of precancerous lesions.